BioSpace News Archive

Replimune Group, Inc. a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended June 30, 2020, and provided operational updates.

MediPharm Labs Corp. a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the appointment of Chris Halyk – former President of Janssen Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson – to its Board of Directors, effective immediately.

Cerecor Inc., a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 2020.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, announced that it will release financial results for the second quarter ended June 30, 2020 before the market opens on Thursday, August 13, 2020.

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, reported positive one year data from patients in Cohorts 4 and 5 of the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration.

- Further advances in recurrent glioblastoma program including submission of End of Phase 2 (“EOP2”) meeting package for MDNA55 - EOP2 meeting scheduled for 29 th September, 2020 with FDA input expected in calendar Q4 2020 - Presented new preclinical data demonstrating the favorable safety profile and best-in-class potential of MDNA11 at ASCO 2020 - Depository Trust Certification (“DTC”) approved in July 2020 TORONTO and HOUSTON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Medicenna Th

Oxford Immunotec Global PLC, a global diagnostics company, announced second quarter 2020 financial results.

Arvinas, Inc., a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.